DiaMedica Therapeutics (DMAC) Stock Highlights

6.41 | +31.62%

2024-12-21 06:25:20

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Statistics

Range Today

4.75 6.41

Volume Today 254.5K

Range 1 Year

2.14 5.74

Volume 1 Year 14.77M

Range 3 Year

1.12 5.74

Volume 3 Year 56.09M

Range 10 Year

0.84 13.774

Volume 10 Year 148.68M

Highlights

Market Capitalization 183.82M (small)

Floating Shares 26.26M

Current Price 6.41

Price To Earnings -8.24

Price To Book 3.44

Earnings Per Share -0.51

Payout Ratio 0%

Performance

Latest +31.62%

1 Month +58.27%

3 Months +57.11%

6 Months +172.77%

1 Year +126.5%

3 Years +83.14%

5 Years +52.26%

10 Years +663.1%

Benchmarks

Market Capitalization

258 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

108 / 368

Free Cashflow

101 / 352

Performance 5 years

81 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.